Developer of a genomic-based artificial intelligence platform designed to offer bespoke health alternatives, as well as provide insight and precision health analysis for benefit of clinical trials. The company's platform offers insights that will be used to initiate clinical trials as well as consult with existing clinical trials in order to improve efficiency and effectiveness, enabling patients to enhance personalized care by improving clinical decision making.

Biodesix is a data-driven diagnostic solutions company that provides lung cancer diagnostic testing and biopharma services. The company provides physicians with diagnostic tests for earlier disease detection, more accurate diagnosis, disease monitoring, and better therapeutic guidance, which may lead to improved patient outcomes. Biodesix discovers, develops, and commercializes multivariate protein diagnostics based on its proprietary mass spectrometry-based discovery platform. VeriStrat, a multivariate serum protein test, is Biodesix’s first product developed with this technology. The commercially available test provides oncologists with information to help them select between erlotinib and single-agent chemotherapy for advanced lung cancer patients. Tests are processed in Biodesix’s CLIA-certified laboratory and results are reported in less than 72 hours. In addition to developing novel diagnostics independently, the company also partners with biotechnology and pharmaceutical companies to develop companion diagnostics to improve the utility of therapeutic agents.

Developer of a drug discovery platform designed to identify significant patterns for developing novel diagnostics and therapies. The company's platform effectively monitors individual responses like artificial neural networks to stratify patients in clinical studies and develop new drugs, enabling physicians to overcome unmet medical needs.

At INNOPLEXUS we are helping organisations move to continuous decision-making by generating broader, deeper and faster insights from structured and unstructured private and public data leveraging cutting-edge, patented Artificial Intelligence, Blockchain and advanced analytics technologies. We aim to transform batch decision making in enterprises into a empowered, inspired and faster continuum.   We focus on industries that need to constantly evaluate and improve their efficiency, reduce cost and mitigate risk to keep up with the changing business environment - like global banking, life sciences, and pharmaceutical companies.   In addition to strengthening research efforts, we work to help healthcare organizations leverage technologies to expedite drug development process across all stages - preclinical, clinical, regulatory and commercial. Whether a drug developer is seeking existing research, a medical researcher is searching for alternative treatments, or a practitioner is attempting to find data on a particular disease - increasing access to relevant information removes roadblocks to discovery and fuels rapid growth.   Our Data as a Service (DaaS) and Continuous Analytics as a Service (CaaS) solutions are helping Fortune 500 companies drive business outcomes. We automate the collection, curation, aggregation and analysis, of billions of data points from thousands of data sources, using machine learning, network analysis, ontologies, computer vision and entity normalization.   Founded in 2015, INNOPLEXUS AG is headquartered in Eschborn Germany with offices in Pune, India, and Hoboken, USA.

Operator of a clinical big data, genomics and medical imaging company intended to accelerate the R&D activity of partners in the biopharmaceutical, diagnostics, and AI industries. The company harnesses extensive genomic and bioinformatics resources for drug and diagnostics discovery and development, from a comprehensive genetic database linked to de-identified medical records of longitudinal clinical data to provide clinical insight, resources, and expertise to a wide range of R&D challenges.

The Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium is a public-private partnership with the mission of transforming drug discovery by accelerating the development of more effective therapies for patients.

Developer of biomarker identification platform intended for improving the quality of life for patients. The company's technology helps in providing proteomics analysis and combines blood analysis, clinical information and bioinformatics, enabling patients to get the right treatment at the right time.

Operator of an AI-enhanced physics-based drug discovery company headquartered in Oostende, Belgium. The company discovers and optimizes active, specific, non-toxic, and patentable small molecules delivering superior drug candidates, and combines artificial intelligence, computational chemistry, and peptide science to accelerate therapeutic compound discovery, streamline hit identification, and optimize leads.

Owkin is a French-American startup that uses artificial intelligence to find the right treatment for every patient. Our focus is to use AI to discover and develop better treatments for unmet medical needs, starting with the fight against cancer. They use AI to identify new drug candidates, de-risk and accelerate clinical trials and build diagnostic tools that improve patient outcomes. Using federated learning, a pioneering collaborative AI framework, Owkin enables medical and biopharma partners to unlock valuable insights from siloed datasets, while protecting patient privacy and securing proprietary data. Owkin was co-founded by Thomas Clozel MD, a clinical research doctor and former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $255 million and became a ‘unicorn’ – a startup valued at more than $1 billion – in November 2021 through a $180 million investment from French biopharma company Sanofi.

Frontier Medicines is a biopharmaceutical company that develops a chemoproteomics platform to accelerate the development of medicines. Its platform integrates advanced computational approaches and machine learning to discover and pharmacologically target new binding pockets on proteins that make them accessible to small-molecule drug discovery and development.